ABNOM
☆ En els resultats de la Stiftung Warentest d'Alemanya de 2022, la satisfacció dels consumidors amb ModelDerm va ser només lleugerament inferior a la de les consultes de telemedicina de pagament.
References
Se sap que el làser Q-switched Nd:YAG tracta eficaçment el nevus d'Ota i condicions similars. Hem realitzat un estudi per veure com funcionava un làser high-fluence 1064 nm Q-switched Nd:YAG a les taques mongols en zones inusuals, sense fer que la pell s'aclarís. Hem estudiat 61 pacients amb aquestes taques, examinant un total de 70 lesions. La meitat de les lesions es van tractar amb el làser, mentre que altres no es van tractar per comparar-les. Hem avaluat els resultats mitjançant una escala i un dispositiu anomenat Mexameter® per mesurar els nivells de melanina. Els pacients van ser seguits durant una mitjana de 14 mesos en el grup de tractament i 18 mesos en el grup d'observació. Al final de l'estudi, vam trobar diferències significatives en les puntuacions de l'escala i els nivells de melanina entre els grups tractats i no tractats, amb el grup tractat amb làser mostrant millors resultats. El làser high-fluence Q-switched Nd:YAG , sense causar il·luminació de la pell, va resultar eficaç i segur per tractar aquestes inusuals taques mongols.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Vam estudiar l'efectivitat i la seguretat d'utilitzar un tractament làser específic per a ABNOM i vam analitzar quins factors podrien afectar el seu bon funcionament. Vam analitzar 110 pacients que tenien ABNOM i van rebre entre dos i nou tractaments amb làser. Vam trobar que el tractament funcionava millor com més temps es feia, però no tan bé en pacients grans. També va funcionar millor en pacients amb pell més clara (tipus III) i zones afectades més petites (menys de 10 cm2) . Tenir melasma juntament amb ABNOM va fer que el tractament fos menys efectiu. El color o el nombre d'àrees afectades no semblava fer cap diferència. Al voltant del 10% dels pacients van tenir taques més fosques després del tractament. El tractament múltiple primerenc va donar bons resultats. Els pacients grans amb pell més fosca i taques més fosques tenen més probabilitats de tenir taques més fosques després del tractament. Per als pacients amb ABNOM i melasma, és millor utilitzar un làser de menor energia per evitar que el melasma empitjori.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Tractament
Els agents blanquejants rarament ajuden. A diferència del melasma, ABNOM es pot millorar amb el tractament amb làser i deixar que s'elimini sense recurrència. El tractament amb làser es pot realitzar de 10 a 20 vegades per tractar ABNOM.
#QS1064 laser